Online inquiry

IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ5750MR)

This product GTTS-WQ5750MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 1
Species	Chimeric
RefSeq	NM_001346897.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	1956
UniProt ID	Q504U8

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5750MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ356MR	IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	20A11-9mer-ALB11
GTTS-WQ868MR	IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	ABBV-176
GTTS-WQ1469MR	IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	ACD22-VCMMAE
GTTS-WQ11835MR	IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	MK-4280
GTTS-WQ15569MR	IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	UNII-FFX71LCS5T
GTTS-WQ7734MR	IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	GLP-1Fc
GTTS-WQ2179MR	IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	ALT-803
GTTS-WQ6742MR	IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	DS 992

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST